Artisan Sold Insulet (PODD) Due to Competition Concerns

Artisan Sold Insulet (PODD) Due to Competition Concerns

Tue, September 8, 2026 at 4:00 PM GMT+3 3 min read

• PODD -1.91%

Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for the "Artisan Mid Cap Fund". The letter can be downloaded here. Global equities rebounded sharply in Q2 2026, recovering from March lows as resilient economic data, strong corporate earnings, and continued AI investment improved investor sentiment despite inflation concerns, delayed rate cuts, and geopolitical uncertainty. The portfolio generated strong absolute returns and outperformed the Russell Midcap® Growth Index, benefiting from semiconductor exposure within IT and strong stock selection in health care and consumer discretionary. Its Investor Class: ARTMX returned 17.86%, Advisor Class: APDMX returned 17.88%, and Institutional Class: APHMX returned 17.93% vs. a 14.55% gain for the index. Healthcare was the largest contributor, with biotech holdings driving gains, while consumer holdings also performed well. Software exposure, aerospace and defense holdings, and communication services positions weighed on relative performance. The fund continues to focus on identifying high-quality growth companies with durable secular trends and attractive valuation opportunities. Please check the fund's top five holdings for its best picks in 2026.

In its second-quarter 2026 investor letter, Artisan Mid Cap Fund highlighted Insulet Corporation (NASDAQ:PODD). Insulet Corporation (NASDAQ:PODD) is an American medical device company known for its Omnipod platform, an insulin delivery system for people with insulin-dependent diabetes. On September 04, 2026, Insulet Corporation (NASDAQ:PODD) closed at $147.48 per share. Over the past month, Insulet Corporation (NASDAQ:PODD) returned 3.24% while its shares lost 57.81% over the past 52 weeks. Insulet Corporation (NASDAQ:PODD) has a market capitalization of $10.23 billion and its stock has traded within a 52-week range of $126.40 to $354.88.

Artisan Mid Cap Fund stated the following regarding Insulet Corporation (NASDAQ:PODD) in its Q2 2026 investor letter:

"Insulet Corporation (NASDAQ:PODD) is the market leader in insulin pumps and offers the only tubeless automated insulin delivery system on the market. The company continues to benefit from strong patient adoption, expanding penetration in the type 2 diabetes market and the advantages of its pharmacy-based distribution model. We exited the position as increasing competition in the insulin pump market has reduced visibility into the company's medium-term growth and market share outlook. While we continue to view Insulet as a high-quality franchise, we believe the growing competitive landscape introduces greater uncertainty around the durability of the profit cycle and chose to redeploy capital into higher conviction opportunities."

Insulet Corporation (NASDAQ:PODD) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 54 hedge fund portfolios held Insulet Corporation (NASDAQ:PODD) at the end of the second quarter which was 55 in the previous quarter. While we acknowledge the potential of Insulet Corporation (NASDAQ:PODD) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered Insulet Corporation (NASDAQ:PODD) and shared Alpha Wealth Funds, LLCs' insight on the company. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

This article is originally published at Insider Monkey.